Compare DENTSPLY SIRONA Inc (XRAY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DENTSPLY SIRONA Inc vs 22nd Century Group Inc — how do they compare? DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B), while 22nd Century Group Inc trades at $2.12 (market cap $1.62M). The key difference: DENTSPLY SIRONA Inc is far larger — about 1351.9× 22nd Century Group Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| XRAY | XXII | |
|---|---|---|
Market Cap | $2.19B | $1.62M |
Sector | Health | Technology |
52-Week High | $14.68 | $594.00 |
52-Week Low | $9.64 | $2.13 |
Enterprise Value | $4.26B | -$2.69M |
Dividend Yield | 5.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.
The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
